Press Release: Akcea’s and Ambry’s expansion of their partnership in honor of the one-year anniversary of the hATTR Compass Genetic Testing Program
no charge genetic testing for hATTR amyloidosis
Alnylam is sponsoring no-charge third-party genetic testing and counseling for individuals who may carry a gene mutation known to be associated with hereditary ATTR (hATTR) amyloidosis. The Alnylam Act® program was developed to reduce barriers to genetic testing and counseling to help people make more informed decisions about their health.
hATTR amyloidosis is an inherited, rapidly progressive, life-threatening disease. It is caused by a mutation in the transthyretin (TTR) gene that results in misfolded TTR proteins accumulating as amyloid fibrils in multiple tissues including the nerves, heart, and gastrointestinal tract. hATTR amyloidosis can lead to significant morbidity, disability, and mortality, with a median survival of 4.7 years following a diagnosis.
While Alnylam provides financial support for this program, tests and services are performed by independent third parties. Healthcare professionals must confirm that patients meet certain criteria to use the program. Alnylam receives de-identified patient data from this program, but at no time does Alnylam receive patient identifiable information. Alnylam receives contact information for healthcare professionals who use this program. Genetic testing is available in the U.S. and Canada. Genetic counseling is only available in the U.S. Healthcare professionals who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use or support any Alnylam product.
Learn more about Alnylam Act ® -
For more information presented by experts in the area of peripheral neuropathies such as CIDP, GBS, and MMN, visit the PolyNeuroExchange (PNE) website (www.polyneuroexchange.com)
(Please note: The Polyneuroexchange is not sponsored by the Peripheral Nerve Society.)